NurExone Biologic Inc. announced that three separate batches of its naïve exosomes demonstrated consistent and significant anti-inflammatory activity in lab tests, reducing key inflammation proteins IL-6 by 88% and TNF-α by 57%. This consistency supports both its therapeutic development of ExoPTEN for spinal cord and optic nerve injuries and its commercial supply plans through Exo-Top for skin and tissue care. The findings address a critical challenge in exosome manufacturing—batch-to-batch consistency—strengthening NurExone's position as it advances production scalability and regulatory compliance. While promising, these in-vitro results do not yet confirm clinical efficacy.
NurExone's recent anti-inflammatory findings provide context for health-sector market activity on Pluang. As of Oct 30, 2026 18:43 WIB, 71 of 150 health stocks rose and 72 fell. Notable movers include BTSG at USD 64.06 with a 6.38% rise and 90% buy orders, TXG at USD 76.56 down 6.12%, and AZN at USD 183.17 up 5.03% with 86% sell orders.
FreightCar America disclosed on October 19, 2026, that it removed 1,285 railcars from its backlog after a customer was unlikely to fulfill contractual obligations, causing its stock to drop 31.4% to $4.02. This sharp decline has led Glancy Prongay Wo...
FirstCash Holdings, Inc. shares fell 14.75% following the October 22, 2026 disclosure of its third quarter financial results, which showed a 28% year-over-year decline in operating income for its American First Finance segment to $33 million. The com...
The global screw compressors market is projected to grow from $13.97 billion in 2026 to $18.38 billion by 2031, at a CAGR of 5.66%. Growth is fueled by rising industrial automation, energy-efficiency regulations, and demand in manufacturing, oil and ...
Enova International's stock fell 23.43% after the company withdrew its application to acquire Grasshopper Bancorp and become a bank holding company. The withdrawal was due to unclear regulatory standards and political pressures cited by Enova. This s...
The global dialysis machines market is forecasted to grow from $17.89 billion in 2026 to $31.54 billion by 2035, at a CAGR of 6.5%. Growth is fueled by rising chronic kidney disease cases, expanding dialysis infrastructure, and innovations like home ...
